ArticleTranslational pediatrics2025
Therapeutic drug monitoring of posaconazole oral suspension in paediatric hematology patients under 13 years of age.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Posaconazole therapeutic drug monitoring in pediatrics: a single-center retrospective study.BMC pediatrics · 2026Article
- Risk Factors for Subtherapeutic Exposure and Hepatotoxicity Threshold of Posaconazole: A Real-World Study in Chinese Patients with Invasive Pulmonary Fungal Infection.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Posaconazole oral suspension is not approved for use in children younger than 13 years of age, and the optimal dosing regimen is unclear. The target trough concentration of posaconazole for the effective prevention of invasive fungal infections in adults is influenced by multiple factors, but reports in children aged <13 years remain limited. Therefore, the primary objective of this study was to evaluate potential risk factors affecting the steady-state trough concentration of oral posaconazole suspension in a large population of Chinese children. Methods: This observational, single-center study retrospectively analyzed pediatric patients younger than 13 years of age who received posaconazole oral suspension for the prevention of invasive fungal disease and implemented therapeutic drug monitoring (TDM) from January 2020 to July 2022. Results: A total of 132 children with 922 steady-state trough concentrations of posaconazole were included in this study. The median dosage of posaconazole by standardized body weight was 14.2 (range, 4.2-51.2) mg/kg/day, with considerable variability. The median posaconazole concentration was 0.81 (range, 0.05-4.5) µg/mL, and the proportion of children reaching the recommended target concentration (≥ 0.7 µg/mL) was 59.5%. The highest percentage of the target concentration (76.8%) was achieved at a median daily dosage of 18 (range, 17-19) mg/kg/day of posaconazole. Multivariate linear regression analysis revealed significant positive correlations between albumin levels (P=0.004) and weight (P<0.001) and posaconazole concentrations. Conversely, treatment with hematopoietic stem cell transplantation (P=0.004), the occurrence of diarrhea (P=0.003), and the coadministration of omeprazole (P<0.001), famotidine (P=0.001) and methylprednisolone (dosage ≥0.7 mg/kg/day) (P=0.006) were associated with significantly reduced posaconazole concentrations. Conclusions: In children under 13 years of age, administration of a dosage regimen of 18 (range, 17-19) mg/kg/day of posaconazole suspension resulted in a higher proportion of children achieving the recommended target concentration. Multiple factors had significant effects on posaconazole trough concentrations. TDM is important for identifying suboptimal posaconazole exposure and making timely dose adjustments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.